<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04638725</url>
  </required_header>
  <id_info>
    <org_study_id>2020-010</org_study_id>
    <nct_id>NCT04638725</nct_id>
  </id_info>
  <brief_title>Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer</brief_title>
  <acronym>SIGHER</acronym>
  <official_title>Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de cancérologie Strasbourg Europe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de cancérologie Strasbourg Europe</source>
  <oversight_info>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, non-randomized, prospective cohort study. The purpose of the study is&#xD;
      to identify constitutional genetic factors associated with histological response, resistance&#xD;
      or sensibility to treatment in human epidermal growth factor receptor 2 (HER2)-positive&#xD;
      breast cancer. 9000 patients will be enrolled in this study. Blood samples will be collected&#xD;
      after informed consent and inclusion in the study. Patients will be treated and followed&#xD;
      according to the standards of their treating center. They will be followed every six months&#xD;
      for five years. Tumor samples will be collected when available.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the SIGHER trial is to create a cohort of 9000 patients with HER2-positive&#xD;
      breast cancer including detailed epidemiologic and treatment data. The distribution of&#xD;
      constitutional genetic variants will be evaluated within groups of patients treated with&#xD;
      different regimes of targeted therapies, identifying variants associated with histological&#xD;
      response, as well as sensitivity or resistance to these therapies.&#xD;
&#xD;
      Blood samples will be collected in two 6ml ethylenediaminetetraacetic acid (EDTA) tubes after&#xD;
      informed consent and inclusion in the study.&#xD;
&#xD;
      As the samples are received at the biological resource center, the plasma will be aliquoted&#xD;
      into a 500 µl tube and frozen at -80° C. DNA will be extracted using standard protocols.&#xD;
      Plasma and DNA will be stored in anticipation of genetic analyses. An aliquot of the DNA&#xD;
      sample will be genotyped for a panel of high-density genetic markers covering the whole&#xD;
      genome for genome-wide association studies.&#xD;
&#xD;
      The collected plasma may also be used for analyses to determine the expression profile of&#xD;
      proteins, alone or combined with genetic factors that allow distinguishing between groups of&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2029</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response (pCR)</measure>
    <time_frame>at the end of enrollment (2 years)</time_frame>
    <description>Constitutional genetic variants using a genome-wide approach will be tested for association with pCR as a function of neoadjuvant treatment targeting HER2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>At the end of the study (7 years)</time_frame>
    <description>Constitutional genetic variants using a genome-wide approach will be tested for association with DFS as a function of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>At the end of the study (7 years)</time_frame>
    <description>Constitutional genetic variants using a genome-wide approach will be tested for association with OS as a function of treatment</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">9000</enrollment>
  <condition>HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>HER2 positive breast cancer treated only with trastuzumab</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>HER2 positive breast cancer treated with pertuzumab</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>HER2 positive breast cancer treated with neratinib</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>HER2 positive breast cancer treated with Trastuzumab emtansine (TDM1)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>HER2 positive breast cancer treated with TDM1 and neratinib</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample for genetic analysis</intervention_name>
    <description>Blood samples will be collected in two 6 ml EDTA tubes after informed consent and inclusion in the study</description>
    <arm_group_label>HER2 positive breast cancer treated only with trastuzumab</arm_group_label>
    <arm_group_label>HER2 positive breast cancer treated with TDM1 and neratinib</arm_group_label>
    <arm_group_label>HER2 positive breast cancer treated with Trastuzumab emtansine (TDM1)</arm_group_label>
    <arm_group_label>HER2 positive breast cancer treated with neratinib</arm_group_label>
    <arm_group_label>HER2 positive breast cancer treated with pertuzumab</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood sample, Tumour paraffin-embedded sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HER2-positive Breast Cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Histological diagnosis of breast adenocarcinoma. Non-metastatic and operable.&#xD;
&#xD;
          -  Prior adjuvant or neoadjuvant treatment with trastuzumab for the current breast cancer&#xD;
&#xD;
          -  Given written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients not able to comply to the protocol assessments for geographic, social or&#xD;
             psychological reasons&#xD;
&#xD;
        Note : Patients are eligible at any time of the follow-up if the adjuvant or neoadjuvant&#xD;
        chemotherapy started after 01/01/2019. Patients treated with trastuzumab in a clinical&#xD;
        trial are eligible in the SIGHER study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Valérie SARTORI</last_name>
    <phone>368767223</phone>
    <phone_ext>33</phone_ext>
    <email>v.sartori@icans.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manon VOEGELIN, PhD</last_name>
    <phone>368767360</phone>
    <phone_ext>33</phone_ext>
    <email>promotion-rc@icans.eu</email>
  </overall_contact_backup>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>November 20, 2020</last_update_submitted>
  <last_update_submitted_qc>November 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

